NCT01424241View on ClinicalTrials.gov

Effects of Sandostatin LAR® in Acromegaly

PHASE4CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

March 31, 2013

Study Completion Date

January 31, 2014

Conditions
Acromegaly
Interventions
DRUG

Sandostatin LAR

Open label dose escalation of Sandostatin LAR 10 mg, 20 mg, 30 mg, up to 40 mg if necessary.

Trial Locations (1)

10032

Columbia University Medical Center, New York

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Columbia University

OTHER